Overcoming multiple myeloma drug resistance in the era of cancer ‘omics’

References

• Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med. 2011;364:1046–1060.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049–3058.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–4695.
   PubMed Web of Science ®Google Scholar
• Abdi J, Chen G, Chang H. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget. 2013;4:2186–2207.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kastritis E, Dimopoulos MA, et al. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015;125:3085–3099.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2011;26:149–157.
   PubMed Web of Science ®Google Scholar
• Horgan RP, Kenny LC. ‘Omic’ technologies: genomics, transcriptomics, proteomics and metabolomics. Obstet Gynaecol. 2011;13:189–195.
   Google Scholar
• Meyer UA, Zanger UM, Schwab M. Omics and drug response. Annu Rev Pharmacol Toxicol. 2013;53:475–502.
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330–1340.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305–2315.
   PubMed Web of Science ®Google Scholar
• Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012;367:826–833.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390.
   PubMed Web of Science ®Google Scholar
• Bhutani M, Landgren O, Usmani SZ, Multiple myeloma: is it time for biomarker-driven therapy? Am Soc Clin Oncol Educ Book. 2015:e493–503. doi: 10.14694/EdBook_AM.2015.35.e493
   Google Scholar
• Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014;25:91–101.
   PubMed Web of Science ®Google Scholar
• Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012;12:335–348.
   PubMed Web of Science ®Google Scholar
• Bahlis NJ. Darwinian evolution and tiding clones in multiple myeloma. Blood. 2012;120:927–928.
   PubMed Web of Science ®Google Scholar
• Richardson PG. The future of myeloma therapy: one size does not fit all. J Oncol Pract. 2016;12:295–296.
   PubMed Web of Science ®Google Scholar
• Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2007;21:164–168.
   PubMed Web of Science ®Google Scholar
• Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151–157.
   PubMed Web of Science ®Google Scholar
• Reece D, Song KW, Fu T, et al. Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood. 2009;114:522–525.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010;24:1769–1778.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Soulier J, Fermand JPP, et al. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone. Leukemia. 2010;24:623–628.
   PubMed Web of Science ®Google Scholar
• Chang H, Jiang A, Qi C, et al. Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leuk Lymphoma. 2010;51:2084–2091.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276–2284.
   PubMed Web of Science ®Google Scholar
• Bergsagel PL, Kuehl WM, Zhan F, et al. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106:296–303.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Braggio E, Mulligan G, et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood. 2008;111:1603–1609.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Miguel J. Prognostic factors and staging in multiple myeloma. Hematol Oncol Clin North Am. 2007;21:1115–1140.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013. Mayo Clin Proc. 2013;88:360–376.
   PubMed Web of Science ®Google Scholar
• Decaux O, Lodé L, Magrangeas F, et al. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the intergroupe francophone du myélome. J Clin Oncol. 2008;26:4798–4805.
   PubMed Web of Science ®Google Scholar
• Prideaux SM, O’Brien E, Chevassut TJ. The RAG model: a new paradigm for genetic risk stratification in multiple myeloma. Bone Marrow Res. 2014;2014:1–9.
   Google Scholar
• Ghadimi BM, Grade M. Cancer gene profiling for response prediction. Methods Mol Biol. 2010;576:327–339.
   PubMedGoogle Scholar
• Jensen EH, McLoughlin JM, Yeatman TJ. Microarrays in gastrointestinal cancer: is personalized prediction of response to chemotherapy at hand? Curr Opin Oncol. 2006;18:374–380.
   PubMed Web of Science ®Google Scholar
• Mariadason JM, Arango D, Shi Q, et al. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 2003;63:8791–8812.
   PubMed Web of Science ®Google Scholar
• Nagasaki K, Miki Y. Molecular prediction of the therapeutic response to neoadjuvant chemotherapy in breast cancer. Breast Cancer. 2008;15:117–120.
   PubMed Web of Science ®Google Scholar
• Schauer M, Janssen K-PP, Rimkus C, et al. Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res. 2010;16:330–337.
   PubMed Web of Science ®Google Scholar
• Anguiano A, Tuchman SA, Acharya C, et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. JCO. 2009;27:4197–4203.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Klein B, Bataille R, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96:574–582.
   PubMed Web of Science ®Google Scholar
• Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020–2028.
   PubMed Web of Science ®Google Scholar
• Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007;109:1692–1700.
   PubMed Web of Science ®Google Scholar
• Zhan F, Barlogie B, Mulligan G, et al. High-risk myeloma: a gene expression based risk-stratification model for newly diagnosed multiple myeloma treated with high-dose therapy is predictive of outcome in relapsed disease treated with single-agent bortezomib or high-dose dexamethasone. Blood. 2008;111:968–969.
   PubMed Web of Science ®Google Scholar
• Amin SB, Yip WKK, Minvielle S, et al. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma. Leukemia. 2014;28:2229–2234.
   PubMed Web of Science ®Google Scholar
• Krishnan SR, Jaiswal R, Brown RD, et al. Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review). Int J Oncol. 2016;49:33–50.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28–35.
   PubMed Web of Science ®Google Scholar
• Anderson KC, Auclair D, Kelloff GJ, et al. The role of minimal residual disease testing in myeloma treatment selection and drug development: current value and future applications. Clin Cancer Res. 2017. doi: 10.1158/1078-0432.CCR-16-2895
   Web of Science ®Google Scholar
• Barnidge DR, Tschumper RC, Theis JD, et al. Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC–MS/MS. J Proteome Res. 2014;13:1905–1910.
   PubMed Web of Science ®Google Scholar
• Kidd BA, Readhead BP, Eden C, et al. Integrative network modeling approaches to personalized cancer medicine. Personal Med. 2015;12:245–257.
   PubMed Web of Science ®Google Scholar
• Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24:289–304.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Oliva L, Cascio P, et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009;113:3040–3049.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CXX, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118:4771–4779.
   PubMed Web of Science ®Google Scholar
• Fall DJ, Stessman H, Patel SS, et al. Utilization of translational bioinformatics to identify novel biomarkers of bortezomib resistance in multiple myeloma. J Cancer. 2014;5:720–727.
   PubMed Web of Science ®Google Scholar
• Egan P, Drain S, Conway C, et al. Towards stratified medicine in plasma cell myeloma. IJMS. 2016;17:1760.
   Google Scholar
• Agnelli L, Tassone P, Neri A. Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. Expert Opin Biol Ther. 2013;13 Suppl 1:68.
   PubMed Web of Science ®Google Scholar
• Stessman HA, Baughn LB, Sarver A, et al. Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. Mol Cancer Ther. 2013;12:1140–1150.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Tiedemann R, Shi C-XX, et al. RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5. Blood. 2011;117:3847–3857.
   PubMed Web of Science ®Google Scholar
• Stessman HA, Mansoor A, Zhan F, et al. Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. Leukemia. 2013;27:2075–2077.
   PubMed Web of Science ®Google Scholar
• Hsieh FY, Tengstrand E, Pekol TM, et al. Elucidation of potential bortezomib response markers in mutliple myeloma patients. J Pharm Biomed Anal. 2009;49:115–122.
   PubMed Web of Science ®Google Scholar
• Micallef J, Dharsee M, Chen J, et al. Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. J Hematol Oncol. 2010;3:1–11.
   PubMed Web of Science ®Google Scholar
• Rees-Unwin KS, Craven RA, Davenport E, et al. Proteomic evaluation of pathways associated with dexamethasone-mediated apoptosis and resistance in multiple myeloma. Br J Haematol. 2007;139:559–567.
   PubMed Web of Science ®Google Scholar
• Abdullah L, Chow E. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med. 2013;2:3.
   PubMedGoogle Scholar
• Abraham J, Salama NN, Azab AK. The role of P-glycoprotein in drug resistance in multiple myeloma. Leuk Lymphoma. 2015;56:26–33.
   PubMed Web of Science ®Google Scholar
• Micallef J, Taccone M, Mukherjee J, et al. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res. 2009;69:7548–7556.
   PubMed Web of Science ®Google Scholar
• Trudel S, Stewart AK, Rom E, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood. 2006;107:4039–4046.
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Lim RS, et al. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood. 1998;92:3025–3034.
   PubMed Web of Science ®Google Scholar
• Pollett JB, Trudel S, Stern D, et al. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood. 2002;100:3819–3821.
   PubMed Web of Science ®Google Scholar
• St-Germain JR, Taylor P, Tong J, et al. Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci USA. 2009;106:20127–20132.
   PubMed Web of Science ®Google Scholar
• Melchor L, Brioli A, Wardell CP, et al. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014;28:1705–1715.
   PubMed Web of Science ®Google Scholar
• Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997.
   PubMed Web of Science ®Google Scholar
• Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471:467–472.
   PubMed Web of Science ®Google Scholar
• Shi J, Wang E, Milazzo JP, et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat Biotechnol. 2015;33:661–667.
   PubMed Web of Science ®Google Scholar
• Stessman HA, Lulla A, Xia T, et al. High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Leukemia. 2014;28:2263–2267.
   PubMed Web of Science ®Google Scholar
• Pietiainen V, Saarela J, von Schantz C, et al. The high throughput biomedicine unit at the institute for molecular medicine Finland: high throughput screening meets precision medicine. CCHTS. 2014;17:377–386.
   Google Scholar
• Kocoglu M, Badros A. The role of immunotherapy in multiple myeloma. Pharmaceuticals. 2016;9:3.
   Web of Science ®Google Scholar
• De Sousa KP, Doolan DL. Immunomics: a 21st century approach to vaccine development for complex pathogens. Parasitology. 2016;143:236–244.
   PubMed Web of Science ®Google Scholar
• Bae J, Prabhala R, Voskertchian A, et al. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients. Leukemia. 2015;29:218–229.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–733.
   PubMed Web of Science ®Google Scholar
• Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma. Clin Cancer Res. 2013;19:1917–1919.
   PubMed Web of Science ®Google Scholar
• Zhou FLL, Meng S, Zhang WGG, et al. Peptide-based immunotherapy for multiple myeloma: current approaches. Vaccine. 2010;28:5939–5946.
   PubMed Web of Science ®Google Scholar
• Hundemer M, Schmidt S, Condomines M, et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol. 2006;34:486–496.
   PubMed Web of Science ®Google Scholar
• Jalili A, Ozaki S, Hara T, et al. Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood. 2005;106:3538–3545.
   PubMed Web of Science ®Google Scholar
• Chiriva-Internati M, Liu Y, Weidanz JA, et al. Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood. 2003;102:3100–3107.
   PubMed Web of Science ®Google Scholar
• Rew SB, Peggs K, Sanjuan I, et al. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24. Clin Cancer Res. 2005;11:3377–3384.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Zhan F, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105:3939–3944.
   PubMed Web of Science ®Google Scholar
• Schuberth PC, Jakka G, Jensen SM, et al. Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. Gene Ther. 2013;20:386–395.
   PubMed Web of Science ®Google Scholar
• Bae J, Tai Y-TT, Anderson KC, et al. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol. 2011;155:349–361.
   PubMed Web of Science ®Google Scholar
• Bae J, Carrasco R, Lee AHH, et al. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma. Leukemia. 2011;25:1610–1619.
   PubMed Web of Science ®Google Scholar
• Bae J, Smith R, Daley J, et al. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. 2012;18:4850–4860.
   PubMed Web of Science ®Google Scholar
• Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61:6846–6850.
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Fujiki F, et al. WT1 peptide vaccine as a paradigm for “cancer antigen-derived peptide”-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide. ACAMC. 2009;9:787–797.
   Google Scholar
• Kuball J, de Boer K, Wagner E, et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol Immunother. 2011;60:161–171.
   PubMed Web of Science ®Google Scholar
• Greiner J, Schmitt A, Giannopoulos K, et al. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica. 2010;95:1191–1197.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Schmitt A, Rojewski MT, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111:1357–1365.
   PubMed Web of Science ®Google Scholar
• Rapoport AP, Aqui NA, Stadtmauer EA, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011;117:788–797.
   PubMed Web of Science ®Google Scholar
• Hobo W, Strobbe L, Maas F, et al. Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. Cancer Immunol Immunother. 2013;62:1381–1392.
   PubMed Web of Science ®Google Scholar
• Walz S, Stickel JS, Kowalewski D, et al. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood. 2015;126:1203–1213.
   PubMed Web of Science ®Google Scholar
• Newell EW, Sigal N, Nair N, et al. Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. Nat Biotechnol. 2013;31:623–629.
   PubMed Web of Science ®Google Scholar
• Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361–370.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754–766.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319–1331.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood. 2015;126:300–310.
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Tomita Y, Yuno A, et al. Cancer immunotherapy using novel tumor‐associated antigenic peptides identified by genome‐wide cDNA microarray analyses. Cancer Sci. 2015;106:505–511.
   PubMed Web of Science ®Google Scholar
• Mu B, Zhang H, Cai X, et al. Screening of multiple myeloma by polyclonal rabbit anti-human plasmacytoma cell immunoglobulin. PLoS One. 2013;8:e59117.
   PubMed Web of Science ®Google Scholar
• Datta P, Linhardt RJ, Sharfstein ST. An 'omics approach towards CHO cell engineering. Biotechnol Bioeng. 2013;110:1255–1271.
   PubMed Web of Science ®Google Scholar
• Orellana CA, Marcellin E, Schulz BL, et al. High-antibody-producing Chinese hamster ovary cells up-regulate intracellular protein transport and glutathione synthesis. J Proteome Res. 2015;14:609–618.
   PubMed Web of Science ®Google Scholar
• Anderson KC. Progress and paradigms in multiple myeloma. Clin Cancer Res. 2016;22:5419–5427.
   PubMed Web of Science ®Google Scholar
• Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148:1293–1307.
   PubMed Web of Science ®Google Scholar